The aim of this study was to assess whether the association between angiotensin-converting enzyme (ACE) inhibitor use and the incidence of treated diabetes mellitus is modified by genetic polymorphisms in the renin-angiotensin system (RAS).In a nested case-control study, treated hypertensive patients were genotyped for ACE (insertion (I)/deletion (D)), angiotensinogen (AGT; M235T) and angiotensin II type 1 receptor (AGTR1; A1166C). Cases of newly treated diabetes were identified based on pharmacy records and controls were not yet drug treated for diabetes (case:control ratio 1:10). Self-administered questionnaires and physical examinations were used to assess risk factors for diabetes mellitus. Logistic regression was used to calculate the relative risk of diabetes associated with ACE inhibitor use relative to other antihypertensive treatment, stratified by the RAS genotypes. Among 205 cases and 2050 controls, homozygous 1166A carriers of the AGTR1 gene had a significantly decreased incidence of diabetes associated with current use of ACE inhibitors (odds ratio, OR: 0.47; 95% CI: 0.26-0.84), whereas this incidence was increased among 1166C allele carriers (OR: 1.32; 95% CI: 0.81-2.14). The interaction OR was 3.21 (95% CI: 1.53-6.75). ACE I allele carriers had a significantly reduced incidence of diabetes associated with ACE inhibitors use (OR: 0.63; 95% CI: 0.41-0.98), whereas DD homozygotes had no reduced risk (OR: 0.95; 95% CI: 0.46-1.96). The risk of diabetes associated with ACE inhibitor use was not significantly modified by the AGT-M235T polymorphism. Treatment with ACE inhibitors in hypertensive subjects significantly reduces the occurrence of diabetes in homozygous 1166A carriers of the AGTR1 gene and carriers of the ACE I allele, but not in 1166C allele carriers of the AGTR1 gene and in homozygous ACE D allele carriers.
Introduction
Essential hypertension is closely associated with type II diabetes mellitus. Both elevated blood pressure and impaired glucose tolerance are key components of the metabolic syndrome, a major cause of cardiovascular morbidity and mortality. 1 The metabolic effects of treatment with antihypertensive agents may be negative (diuretics, b-blockers), neutral (calcium antagonists) or positive (angiotensin-converting enzyme, ACE inhibitors and angiotensin II type 1 receptor blockers, ARBs). A recent meta-analysis assessed that the relative risk reduction of type II diabetes mellitus by ACE inhibitors or ARB therapy compared to diuretic therapy was 23 and 43%, respectively. 2 The mechanisms through which ACE inhibitors and ARBs reduce the risk of diabetes mellitus remain uncertain, although several mechanisms, such as decreased renal potassium wasting, and improved islet blood flow and pancreatic b-cell perfusion by reducing angiotensin II-mediated vasoconstriction in the pancreas, have been proposed. 3 Polymorphisms in three genes that code for major components of the renin-angiotensin system (RAS), angiotensinogen (AGT) M235T, ACE insertion/deletion (I/D), and angiotensin II type 1 receptor (AGTR1) A1166C, may influence the response to these antihypertensive agents and thus the incidence of diabetes. The aim of this study was to assess whether the association between the use of ACE inhibitors and the incidence of diabetes is modified by genetic polymorphisms in RAS genes.
Materials and methods/subjects
We performed a nested case-control study among treated hypertensive patients. The Pharmaco-Morbidity Record Linkage System (PHARMO-RLS) was used to identify patients treated with antihypertensive drugs. PHARMO-RLS links drug dispensing histories from a representative sample of Dutch community pharmacies to the national registrations of hospital discharges (LMR) from 1985 onward. Currently, the base population of PHARMO-RLS covers about two million community-dwelling inhabitants of about 50 population-defined areas in the Netherlands. As data from two population-based studies overlap with the PHARMO-RLS population, these could be used to collect data on genotypes and potential risk factors for diabetes mellitus (Figure 1) .
The Monitoring Project on Cardiovascular Risk Factors was a population-based cross-sectional study of cardiovascular disease risk factors conducted in three Dutch cities (Amsterdam, Maastricht and Doetinchem). In Doetinchem, 12 449 men and women between the age of 20 and 59 years from a total population of circa 40 000 inhabitants during 1987-1991, were examined. Details have been published elsewhere. 4 Of these Doetinchem subjects, 9336 were also linked to the PHARMO-RLS and of 571 subjects both pharmacy records and genotype data were available for treated hypertensive subjects.
In a pharmacogenetic study including 4985 treated hypertensive subjects specific genetic polymorphisms were examined for the modification of the effect of antihypertensive drugs on the risk of myocardial infarction in a selection of PHARMO-RLS participants. 5 Of these 4985 subjects, 1275 had both pharmacy records available and genotype data were available for treated hypertensive subjects.
In total, 1846 treated hypertensive patients with both pharmacy records and genotype data were available from both populations.
Data collection
The PHARMO-RLS provides records containing the name of the dispensed drugs, day of dispensing, number of units dispensed, prescribed daily dose and the Anatomical Therapeutical Chemical code of the drug. In both Monitoring Project on Cardiovascular Risk Factors and the pharmacogenetic study, data were obtained on demographic variables, cardiovascular diseases and risk factors. In the Monitoring Project on Cardiovascular Risk Factors Study, venous blood samples were obtained for DNA extraction whereas in the pharmacogenetic study buccal swabs were used to collect DNA. Genetic variation in the renin-angiotensin system Ö Bozkurt et al ACE I/D 7 and AGTR1 1166A/C 8 polymorphisms, in the Monitoring Project on Cardiovascular Risk Factors Study were previously described. Genotyping in the pharmacogenetic study was determined using a multiplex single base extension (SBE) method. Multiplex SBE was performed using SNaPshot as described by the manufacturer (Applied Biosystems, Foster City, CA, USA). This method was described earlier, 9 but adapted to a new set of polymorphisms for the pharmacogenetic study. The multiplex assay was validated on a set of 100 DNA samples that had previously been genotyped with an alternative technique; this technique concerned a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Basel, Switzerland) and has been described in detail previously. 10 All three RAS polymorphisms were concordant. In the Monitoring Project on Cardiovascular Risk Factors Study, the ACE I/D polymorphism was directly assessed whereas in the pharmacogenetic study the ACE I/D polymorphism was determined by detecting ACE 4656 þ CT observed on the SNaPshot as ACE (G4656C). The G4656C polymorphism in the 3 0 -untranslated region of the ACE gene consists of a repetition of two or three CT dinucleotides, which is in complete linkage disequilibrium with ACE (I/D).
Genotyping

9,11
Outcome and exposure definition The outcome of interest was incident diabetes. Pharmacy records were used to assess incident diabetes (cases). Incident cases of diabetes were defined as those having a first prescription for oral anti-diabetic drugs or insulin at least 1 year after the date of entry in PHARMO-RLS. Cases were assigned an index date, which was defined as the day the first anti-diabetic drug prescription was dispensed. For each case we selected 10 controls who also received anti-hypertensive drugs but who were not (yet) treated with anti-diabetic drugs at the index date of the case. We used risk-set sampling of cases and controls which means that one subject may serve as control multiple times for different cases and also that a control may become a case later on. 12 Exposure to anti-hypertensive drugs was ascertained from pharmacy records and was defined as current, past or never use. We also calculated the dose of current use of ACE inhibitors according to the defined daily dose (DDD), which is the average daily dose of a drug for its main indication in adults, and is recommended by the World Health Organization for drug utilization studies. 13 In sensitivity analyses we also categorized subjects as current users of ACE inhibitors, ARB, thiazides and other anti-hypertensives (for example, b-blockers, calcium antagonists). In these analyses the group of other anti-hypertensives served as the reference group.
Data analysis
Analyses were performed using SPSS (version 12.1; SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean±standard deviation. Deviations from Hardy-Weinberg equilibrium were checked using w 2 -tests. Unconditional logistic regression analysis was used to study the association between ACE Inhibitor use and incident diabetes. Then, all analyses were stratified by ACE (I/D), AGT (M235T) and AGTR1 (A1166C) genotypes to study interaction. We considered age, gender, smoking, physical activity, body mass index and alcohol use as potential confounders. Because of the assumed association of the ACE DD genotype with higher incidence of diabetes, the II and ID genotypes were grouped together in the analysis, and crude and adjusted odds ratio (OR) were computed for both groups separately. For the analysis of the AGT gene the TT and the MT genotypes were analysed together. Similarly, the AGTR1 CC and CA genotypes were grouped together and compared with AA genotype.
The presence and statistical significance of interaction OR was tested by adding an interaction term (ACE Inhibitor Â Genotype) to the logistic regression model. The interaction OR can be interpreted as the ratio of the OR in subjects with a susceptible genotype and the OR in subjects without this genotype. An interaction OR of 1 indicates no interaction on the multiplicative scale. 14 We also calculated the relative excess risk due to interaction (RERI) according to Rothman and Greenland. 13 A RERI of 0 indicates no interaction on the additive scale.
Results Table 1 shows the baseline characteristics of the 205 cases and 2050 controls. Cases were significantly more often obese and used more alcohol than controls. Of the anti-hypertensive drugs studied, only the frequency of thiazide diuretic use differed significantly between cases and controls. All polymorphisms were in Hardy-Weinberg equilibrium. The ACE, AGT and AGTR1 genotype frequencies did not differ significantly between cases and controls.
Overall use of ACE inhibitors was not statistically significantly associated with a reduced incidence of diabetes (adjusted OR: 0.74; 95% CI: 0.51-1.06). When stratified on dose of ACE inhibitor we found that a dose of o1 DDD per day was not associated with the incidence of diabetes (adjusted OR: 1.08; 95% CI: 0.61-1.93), whereas current use of a dose X1 DDD per day was significantly associated with a reduced risk of diabetes (adjusted OR: 0.64; 95% CI: 0.42-0.97). Table 2 shows the associations between the use of ACE inhibitors and incidence of diabetes stratified by genetic polymorphisms in the RAS. Subjects carrying the AA genotype of the AGTR1 gene had a significantly lower incidence of diabetes Genetic variation in the renin-angiotensin system Ö Bozkurt et al when they were current users of ACE inhibitors (adjusted OR: 0.47; 95% CI: 0.26-0.84). Subjects with the AA genotype who used X1 DDD per day had a lower relative risk of diabetes compared to subjects who used o1 DDD per day. This association was not seen in carriers of the C allele (adjusted OR: 1.32; 95% CI: 0.81-2.14). C allele carriers who usedX1 DDD per day had a higher relative risk of diabetes compared to subjects who used o1 DDD per day. We also assessed the interaction between the use of ACE inhibitors and polymorphisms in the RAS on the incidence of diabetes (Table 3 ). The use of ACE inhibitors in AGTR1 C allele carriers was associated with significantly higher incidence of diabetes compared to AA genotype (adjusted interaction OR 3.21; 95% CI: 1.53-6.75). This interaction was particularly present among those who used X1 DDD per day (adjusted interaction OR: 8.30; 95% CI: 3.27-21.1). ACE inhibitor users with the ACE DD genotype had a non-significant higher incidence of diabetes compared to ACE I allele carriers (adjusted interaction OR: 2.03; 95% CI: 0.92-4.46). Current users of ACE inhibitors carrying the T allele of the AGT gene polymorphism had a twofold higher incidence (adjusted interaction OR: 2.03; 95% CI: 0.63-6.50) of diabetes in comparison to MM carriers, though not statistically significant.
In sensitivity analyses, adjustment for the combined use of thiazides or b-blockers did not change the results (interaction OR for AGTR1 C allele: 3.23; 95% CI: 1.53-6.82), ACE DD genotype (adjusted interaction OR: 1.98; 95% CI: 0.90-4.36) and AGT T allele (adjusted interaction OR: 2.07; 95% CI: 0.64-6.66). Furthermore, separate classification of subjects as current users of ACE inhibitors, ARB, thiazides and other anti-hypertensives also did not change the results (adjusted interaction for AGTR1 C allele: 2.73; 95% CI: 1.20-6.18), ACE DD genotype (adjusted interaction OR: 1.59; 95% CI: 0.63-4.01) and AGT T allele (adjusted interaction OR: 2.00; 95% CI: 0.53-7.62).
On an additive scale the RERI was significantly increased for ACE inhibitor users with the AGTR1 C allele (RERI: 0.85; 95% CI: 0.31-1.37) and subjects with the ACE DD genotype (RERI: 0.63; 95% CI: 0.16-1.43). The RERI for ACE inhibitors users with the T allele of the AGT gene was 0.31 (95% CI: À0.39-1.03).
Discussion
In this study, the risk of diabetes associated with the use of ACE inhibitors was strongly modified by the AGTR1 A1166C and modestly by the ACE I/D polymorphism. Subjects with the AGTR1 AA genotype who used ACE inhibitors had a 53% decreased risk of diabetes compared to users of other antihypertensive drugs whereas among subjects carrying the AGTR1 C allele no such reduction was observed. Carriers of the I allele of the ACE gene who used ACE inhibitors had a reduction in their Genetic variation in the renin-angiotensin system Ö Bozkurt et al Adjusted for index date, obesity and use of alcohol.
Genetic variation in the renin-angiotensin system Ö Bozkurt et al risk for diabetes of 37%. No reduction was seen in DD homozygous subjects.
To appreciate the findings in this study, some aspects need to be discussed. Confounding is always an issue when causal analyses are conducted using observational data. The interactions that we found are probably less vulnerable to confounding because physicians prescribe ACE inhibitors without knowledge of the genotype. Although we adjusted for many important potential confounding factors, we cannot exclude residual confounding due to unmeasured or inaccurately measured factors. Another limitation of the current study is the genotyping of the ACE gene polymorphism in the pharmacogenetic study, which was not assessed directly. However, the G4656C SNP of the ACE gene is almost in complete linkage disequilibrium with the ACE I/D polymorphism and would not affect our results in a major way. Our analyses were limited to one polymorphism per gene and we could not take other possible variations in these genes into account. Furthermore, our sample size was not large enough to study gene-gene-drug interactions. Finally, there are other genes of the RAS which might be important in modifying the response to ACE Inhibitor such as the aldosterone synthase (CYP11B2) gene and angiotensin II type 2 receptor gene. 15, 16 In this study we considered receiving a first time oral anti-diabetic prescription as a reliable proxy for incident diabetes although the time of onset may be much earlier than the first prescription. Furthermore, we will have missed incident diabetes cases that were not severe enough to be treated. We do not expect this to be differential for the various anti-hypertensive drug classes, and therefore the influence on our results will probably be a small underestimation of the effect of ACE inhibitors on the incidence of diabetes mellitus and also of its interaction with the genetic polymorphisms we studied.
The strengths of this study are that we had complete information on most risk factors that are important when considering possible anti-hypertensive drug-gene interactions and we also had a reasonable sample size. This is the first study into the influence of genetic polymorphisms on the risk of diabetes associated with ACE Inhibitor therapy. The mechanism through which inhibition of ACE leads to a significant higher risk of diabetes among C allele carriers of the AGTR1 remains unclear. The AGTR1 A1166C polymorphism has previously been associated with both an increased and decreased blood pressure response to ACE inhibitors. 17 Although the DD polymorphism of the ACE gene is associated with higher circulating ACE plasma levels in Caucasians, 18 no study has focused on the modifying effect of the RAS genes on the response to ACE inhibitors with regard to the incidence of diabetes. Almost 50% of the variance of serum ACE levels can be predicted by the ACE insertion/deletion polymorphism 7 and ACE inhibitors may improve insulin-stimulated glucose uptake of the whole organism by increasing the glucose uptake by the skeletal musculature. 19 Perhaps that the DD genotype carriers compared to I allele carriers need higher doses of ACE inhibitors to achieve a similar effect. 20 The TT genotype of the AGT gene polymorphism has been associated with elevated AGT levels, hypertension, increased heart disease risk and improved blood pressure in response to ACE inhibitors. 21 The homozygous TT state was associated with approximately 20% increase in plasma AGT and elevated plasma AGT levels have been demonstrated in insulin-resistant states. 22 Consequently subjects with the AGT T allele might need higher doses of ACE inhibitors to achieve a similar effect on the incidence of diabetes compared to AGT MM homozygous subjects. However, we were not able to show this in our study.
In conclusion, treatment with ACE inhibitors in hypertensive subjects significantly reduces the occurrence of diabetes in homozygous 1166A carriers of the AGTR1 gene and carriers of the ACE insertion allele, but not in 1166C allele carriers of the AGTR1 gene and in homozygous ACE deletion allele carriers.
